<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03164291</url>
  </required_header>
  <id_info>
    <org_study_id>072</org_study_id>
    <nct_id>NCT03164291</nct_id>
  </id_info>
  <brief_title>Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex</brief_title>
  <official_title>Clinical Efficacy of Rifabutin in the Treatment of Serious and Life Threatening Infections Due to Mycobacterium Avium Complex, or Drug Resistant Mycobacterium Tuberculosis, or Other Drug Resistant Mycobacterium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at Tyler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at Tyler</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections
      who have failed or are intolerant of rifampin.

      Rifabutin may be a reasonable alternative agent in patients who fail rifampin or or
      intolerant of rifampin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rifabutin dosage 150-300 mg daily( depending upon age, and clinical conditions) in NTM
      patients who fail treatment with rifampin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1984</start_date>
  <completion_date type="Actual">May 18, 2017</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and microbiological outcomes (e.g. clinical symptoms, laboratory cultures)</measure>
    <time_frame>6 mos</time_frame>
    <description>neg cultures X3( sputum conversion)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiological Cultures</measure>
    <time_frame>1year</time_frame>
    <description>neg cultures for 1 yr on treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Nontuberculous Mycobacterial Infections</condition>
  <arm_group>
    <arm_group_label>Rifabutin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections or other NTM disease who fail therapy with other drugs ( i.e., rifampin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifabutin</intervention_name>
    <description>Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status</description>
    <arm_group_label>Rifabutin</arm_group_label>
    <other_name>mycobutin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults age 18 and older with positive acid-fast bacilli smears and cultures for
             drug-resistant mycobacteria

        Exclusion Criteria:

          -  Children less than 18 years of age

          -  Pregnancy

          -  Low platelet count, except with very serious disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard J Wallace, Jr, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Center at Tyler</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William B Girard, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas Health Science Center IRB Chair</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2008</study_first_submitted>
  <study_first_submitted_qc>May 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at Tyler</investigator_affiliation>
    <investigator_full_name>Richard J. Wallace, Jr., M.D.</investigator_full_name>
    <investigator_title>Chairman Department of Microbiology</investigator_title>
  </responsible_party>
  <keyword>MAC and NTM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifabutin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

